Released on: November 9, 2007, 9:12 am

Press Release Author: GTCbio

Industry: Pharmaceuticals

Press Release Summary: Kenna Anderes of Pfizer Global R&D, Michael Shi of Novartis
and Joseph Paul Eder of AstraZeneca to give featured presentations at Oncology
Biomarkers: From Discovery to Validation conference on January 14-15, 2008.

Press Release Body: MONROVIA, CA - Kenna Anderes, Director of Oncology Biomarkers at
Pfizer Global Research & Development, Michael Shi, Director and Biomarker Project
Leader of Exploratory Oncology Development at Novartis Pharmaceutical Corporation
and Joseph Paul Eder, Senior Director of Oncology Clinical Research Discovery
Medicine at AstraZeneca will give featured presentations at GTCbio's Oncology
Biomarkers: From Discovery to Validation conference on January 14-15, 2008 in San
Francisco, CA.

Dr. Anderes will present on Pfizer's emphasis on imaging biomarkers for oncology
programs. Pfizer considers oncology pharmaceuticals and therapeutics to be a top
priority, and focuses on biomarkers in their clinical applications and drug
development.

Dr. Shi will present on biomarker application in oncology clinical development. He
will discuss the application of biomarkers to address key challenges and
opportunities in developing novel targeted cancer therapeutics. The main challenges
in cancer therapeutics and treatment are to verify the impact of novel drugs on
targets/pathways by monitoring pharmacodynamic biomarkers, to evaluate molecular
response as an early clinical efficacy read-out, to increase drug development
predictability and to give the right drug to the right patients at the optimal dose.

Dr. Eder will discuss biomarkers for clinical decisions in phase I and II trials at
AstraZeneca. AstraZeneca repeatedly employs biomarkers in early and late stages of
their clinical trials and views their role as critical in cancer drug development.

The Oncology Biomarkers: From Discovery to Validation conference features
presentations on future methods and technologies for oncology biomarker discovery
and validation, challenges to clinical translation of biomarkers, clinical
application and development of oncology biomarkers and enabling biomarkers in cancer
drug development. For more information, visit www.gtcbio.com.


ABOUT GTCbio

GTCbio organizes conferences specifically for the biomedical and biopharmaceutical
industries. Our goal is to facilitate the exchange of biopharmaceutical and
biomedical intelligence between industry leaders, academic and government
organizations, and the financial community.

GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company
founded in 2002.

Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com

Web Site: http://www.gtcbio.com

Contact Details: GTCbio
434 W. Foothill Blvd.
Monrovia, CA 91016

Phone: 626) 256-6405
Fax: 626) 256-6460
http://www.gtcbio.com